626. Aggressive Lymphomas: Epidemiological Excluding Prospective Clinical Trials: Poster II

Diffuse large B cell lymphoma A study of second primary malignancies among adults in the United States

Baseline CD4 count is associated with early mortality in HIV associated lymphoma A retrospective cohort study

Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL Results from a large real world cohort

Anatomical localization based analysis of de novo secondary cns lymphoma

Impact of high dose methotrexate in both central nervous system relapse and systemic progression in high risk DLBCL A retrospective analysis of a brazilian cohort

Tumor specific risk of acute kidney injury A multi cancer comparison across matched real world cohorts

Consolidation Cons and maintenance Maint approaches in primary central nervous system lymphoma PCNSL after high dose methotrexate induction in transplant ineligible patients

Integrating genomic features for prognosis in Chinese patients  with B cell lymphoma following R CHOP therapy

Concurrent viral infection as an adverse prognostic factor in diffuse large B cell lymphoma not otherwise specified

A predictive model based on NCCN IPI and 2 pirnas for prognostic risk stratification of diffuse large B cell lymphoma DLBCL

Age at diagnosis shapes stage and survival in diffuse large B cell lymphoma A 22 year population based study of 94 598 SEER patients

Improved survival with third line CAR T therapy vs alternative treatment in DLBCL A propensity score–matching analysis

Sequencing CD20 directed bispecific antibody and CD19 directed CAR T cell therapy in large B cell lymphoma A multicenter real world study

Aggressive lymphomas that are treated early have worse outcomes Counterintuitive results from a national database study

High levels of soluble TREM2 predict poor survival outcomes and facilitate the expansion of immunosuppressive monocytic lineage cells in patients with DLBCL